Head and Neck Study Presented by Robert Haddad, MD
Dana-Farber's Dr. Robert Haddad says research shows the combination of a PD1 with anti-LAG3 +/- anti-TIM3 does not improve outcomes in metastatic disease, raising the question of whether to look at this combo earlier, in the neoadjuvant setting.
Dr Haddad received his MD Degree from St. Joseph University French School of Medicine in Beirut. He completed his residency in internal medicine at St Luke's Roosevelt Medical Center in New York City, and completed a fellowship in hematology ...
